Reuters -- Astellas Pharma, Japan’s No.2 drugmaker, cut its outlook further below market expectations as tough competition from generic drugmakers, the yen’s strength and R&D costs took their toll.
Reuters -- Astellas Pharma, Japan’s No.2 drugmaker, cut its outlook further below market expectations as tough competition from generic drugmakers, the yen’s strength and R&D costs took their toll.
